Pemetrexed-induced lipodermatosclerosis: clinical course and management of a rare cutaneous toxicity

We present the case of a 67-year-old male with stage IV lung adenocarcinoma who developed pemetrexed-induced lipodermatosclerosis (LDS) and a flare of polymyalgia rheumatica (PMR) during chemotherapy treatment. Initially misdiagnosed as cellulitis, the patient experienced progressive skin toxicity t...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Current problems in cancer. Case reports Ročník 19; s. 100386
Hlavní autoři:	Kahlon, Navkirat, Vallepu, Shirisha, Gowda, Anusha Manje, Baddam, Sujatha
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Elsevier Inc 01.09.2025 Elsevier
Témata:	Chemo side effect Drug toxicity Hematology, Oncology, and Palliative Medicine Lung cancer treatment Rare side effect Chemo side effect Lung cancer treatment Drug toxicity Rare side effect
ISSN:	2666-6219, 2666-6219
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	We present the case of a 67-year-old male with stage IV lung adenocarcinoma who developed pemetrexed-induced lipodermatosclerosis (LDS) and a flare of polymyalgia rheumatica (PMR) during chemotherapy treatment. Initially misdiagnosed as cellulitis, the patient experienced progressive skin toxicity that was ultimately recognized as LDS, associated with pemetrexed. The management of PMR flares and LDS was complex, requiring steroid therapy adjustments and the introduction of pentoxifylline. This case highlights the need for awareness of chemotherapy-induced skin toxicity and the challenges of managing underlying autoimmune conditions in cancer treatment.
ISSN:	2666-6219 2666-6219
DOI:	10.1016/j.cpccr.2025.100386